GLP-1 Market
LLY $1152.44 ▲ +1.3% NVO $43.19 ▲ +3.5% PFE $27.64 ▲ +0.7% VKTX $29.36 ▼ -0.5% KLRA $12.92 ▲ +1.7% GPCR $35.10 ▼ -1.1% RHHBY $54.60 ▼ -1.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Doxecitine and Doxribtimine

Company
Cristina Domínguez González
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
1 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

1 recruiting study currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 18, 2026

Find a Clinical Trial Near Me

See recruiting studies for Doxecitine and Doxribtimine and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT06754098

    Doxecitin and Doxribthymine in Adult Subjects With Thymidine Kinase 2 (TK2) Deficiency

    Not yet reported Cristina Domínguez González 15 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Thymidine Kinase 2 (TK2 ) Deficiency, Mitochondrial Myopathies
    View official trial listing →
  • Completed NCT NCT03845712

    An Open-Label Study of Continuation Treatment With Combination Pyrimidine Nucleosides in Patients With TK2 Deficiency

    Not yet reported UCB BIOSCIENCES, Inc. 47 participants Est. completion 2026-08-26 8 sites Stand-alone
    Other conditions: Thymidine Kinase 2 Deficiency
    View official trial listing →
  • Available NCT NCT06590493

    Doxecitine and Doxribtimine-Expanded Access

    UCB BIOSCIENCES, Inc.
    Other conditions: Thymine Kinase 2 Deficiency
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.